Abstract
Several studies have been conducted over the years to unravel the structural information on the receptors that bind to tumor necrosis factor receptor-associated factor (TRAF) and the driving forces for the TRAF/receptor complex. In addition, studies have also been performed to highlight the influence of TRAF malfunctioning and mutations on the development of human disease. However, a holistic study that systematically summarizes the available information and the existing clinical trends towards development of the TRAF-targeting drugs has not been conducted to date. Herein, I reviewed existing research that focused on the structural information of various receptors recognized by the different members of the TRAF family. I also reviewed studies on the different human diseases that occur due to TRAF malfunctioning or mutations as well as the clinical trials undertaken to treat TRAF-associated diseases.
This is a preview of subscription content, log in via an institution to check access.
(Park 2018)
Similar content being viewed by others
References
Abdul-Sater AA, Edilova MI, Clouthier DL, Mbanwi A, Kremmer E, Watts TH (2017) The signaling adaptor TRAF1 negatively regulates toll-like receptor signaling and this underlies its role in rheumatic disease. Nat Immunol 18:26–35. https://doi.org/10.1038/ni.3618
Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S, Spiegel S (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465:1084–1088. https://doi.org/10.1038/nature09128
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115–130. https://doi.org/10.1016/j.ccr.2007.07.004
Arch RH, Gedrich RW, Thompson CB (1998) Tumor necrosis factor receptor-associated factors (TRAFs)—A family of adapter proteins that regulates life and death. Genes Dev 12:2821–2830. https://doi.org/10.1101/gad.12.18.2821
Arkee T, Bishop GA (2020) TRAF family molecules in T cells: multiple receptors and functions. J Leukoc Biol 107:907–915. https://doi.org/10.1002/JLB.2MR1119-397R
Arthur JF, Shen Y, Gardiner EE, Coleman L, Murphy D, Kenny D, Andrews RK, Berndt MC (2011) TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 9:163–172. https://doi.org/10.1111/j.1538-7836.2010.04091.x
Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203. https://doi.org/10.1111/j.1471-4159.2005.03181.x
Baranzini SE, Khankhanian P, Patsopoulos NA, Li M, Stankovich J, Cotsapas C, Sondergaard HB, Ban M, Barizzone N, Bergamaschi L, Booth D, Buck D, Cavalla P, Celius EG, Comabella M, Comi G, Compston A, Cournu-Rebeix I, Dalfonso S, Damotte V, Din L, Dubois B, Elovaara I, Esposito F, Fontaine B, Franke A, Goris A, Gourraud PA, Graetz C, Guerini FR, Guillot-Noel L, Hafler D, Hakonarson H, Hall P, Hamsten A, Harbo HF, Hemmer B, Hillert J, Kemppinen A, Kockum I, Koivisto K, Larsson M, Lathrop M, Leone M, Lill CM, Macciardi F, Martin R, Martinelli V, Martinelli-Boneschi F, McCauley JL, Myhr KM, Naldi P, Olsson T, Oturai A, Pericak-Vance MA, Perla F, Reunanen M, Saarela J, Saker-Delye S, Salvetti M, Sellebjerg F, Sorensen PS, Spurkland A, Stewart G, Taylor B, Tienari P, Winkelmann J, Zipp F, Ivinson AJ, Haines JL, Sawcer S, DeJager P, Hauser SL, Oksenberg JR, Co IMSG, Consor WTCC (2013) Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet 92:854–865. https://doi.org/10.1016/j.ajhg.2013.04.019
Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M, Wang N, Idris AI (2020) Combined administration of a small-molecule inhibitor of TRAF6 and docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Lett 488:27–39. https://doi.org/10.1016/j.canlet.2020.05.021
Bradley JR, Pober JS (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20:6482–6491. https://doi.org/10.1038/sj.onc.1204788
Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R (2009) Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom’s macroglobulinemia. Cancer Res 69:3579–3588. https://doi.org/10.1158/0008-5472.CAN-08-3701
Camilleri-Broet S, Cremer I, Marmey B, Comperat E, Viguie F, Audouin J, Rio MC, Fridman WH, Sautes-Fridman C, Regnier CH (2007) TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene 26:142–147. https://doi.org/10.1038/sj.onc.1209762
Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL (2007) Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 110:4455–4463. https://doi.org/10.1182/blood-2007-05-088682
Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, van den Berg S, van den Berg S, Soehnlein O, Winkels H, Beckers L, Lievens D, Driessen A, Kusters P, Biessen E, Garcia-Martin R, Klotzsche-von Ameln A, Gijbels M, Noelle R, Boon L, Hackeng T, Schulte KM, Xu A, Vriend G, Nabuurs S, Chung KJ, Willems van Dijk K, Rensen PC, Gerdes N, de Winther M, Block NL, Schally AV, Weber C, Bornstein SR, Nicolaes G, Chavakis T, Lutgens E (2014) Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci USA 111:2686–2691. https://doi.org/10.1073/pnas.1400419111
Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR (2017) Combined TRAF6 targeting and proteasome blockade has anti-myeloma and anti-bone resorptive effects. Mol Cancer Res 15:598–609. https://doi.org/10.1158/1541-7786.MCR-16-0293
Chung JY, Park YC, Ye H, Wu H (2002) All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115:679–688. https://doi.org/10.1242/jcs.115.4.679
Chung JY, Park HR, Lee SJ, Lee SH, Kim JS, Jung YS, Hwang SH, Ha NC, Seol WG, Lee J, Park BJ (2013) Elevated TRAF2/6 expression in Parkinson’s disease is caused by the loss of Parkin E3 ligase activity. Lab Invest 93:663–676. https://doi.org/10.1038/labinvest.2013.60
Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L (2009) Mutations of multiple genes cause deregulation of NF-kappa B in diffuse large B-cell lymphoma. Nature 459:717-U124. https://doi.org/10.1038/nature07968
Culpan D, Cram D, Chalmers K, Cornish A, Palmer L, Palmer J, Hughes A, Passmore P, Craig D, Wilcock GK, Kehoe PG, Love S (2009) TNFR-associated factor-2 (TRAF-2) in alzheimer’s disease. Neurobiol Aging 30:1052–1060. https://doi.org/10.1016/j.neurobiolaging.2007.10.014
Deshaies RJ, Joazeiro CA (2009) Ring domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434. https://doi.org/10.1146/annurev.biochem.78.101807.093809
Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, Jiang H, Yi Q, Hou J (2011) Polymorphisms of nuclear factor-kappaB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica 96:729–737. https://doi.org/10.3324/haematol.2010.030577
Gallego-Fabrega C, Carrera C, Reny JL, Fontana P, Slowik A, Pera J, Pezzini A, Serrano-Heras G, Segura T, Marti-Fabregas J, Muino E, Cullell N, Montaner J, Krupinski J, Fernandez-Cadenas I (2016) TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke. Stroke 47:1180–1186. https://doi.org/10.1161/Strokeaha.115.012237
Gao L, Wang PX, Zhang YX, Yu CJ, Ji YX, Wang XZ, Zhang P, Jiang X, Jin H, Huang Z, Zhang ZR, Li HL (2016) Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. J Hepatol 65:125–136. https://doi.org/10.1016/j.jhep.2016.03.006
Guo CC, Zhang LJ, Nie LH, Zhang N, Xiao D, Ye XG, Ou ML, Liu Y, Zhang BH, Wang M, Lin HS, Yang G, Jing CX (2016) Association of polymorphisms in the MyD88, IRAK4 and TRAF6 genes and susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a southern Han Chinese population. Mol Cell Endocrinol 429:114–119. https://doi.org/10.1016/j.mce.2016.04.003
Hacker H, Tseng PH, Karin M (2011) Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 11:457–468. https://doi.org/10.1038/nri2998
Hessler N, Geisel MH, Coassin S, Erbel R, Heilmann S, Hennig F, Hoffmann B, Jockel KH, Moebus S, Moskau-Hartmann S, Nurnberg G, Nurnberg P, Vens M, Klockgether T, Kronenberg F, Scherag A, Ziegler A (2016) Linkage and association analysis identifies TRAF1 influencing common carotid intima-media thickness. Stroke 47:2904–2909. https://doi.org/10.1161/STROKEAHA.116.013943
Hoeflich KP, Yeh WC, Yao Z, Mak TW, Woodgett JR (1999) Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1). Oncogene 18:5814–5820. https://doi.org/10.1038/sj.onc.1202975
Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387–396. https://doi.org/10.1016/s1074-7613(00)80252-6
Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, Yamamoto T (2000) Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254:14–24. https://doi.org/10.1006/excr.1999.4733
Jiang X, Deng KQ, Luo YX, Jiang DS, Gao L, Zhang XF, Zhang P, Zhao GN, Zhu XY, Li HL (2015) Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophy. Hypertension 66:356–367. https://doi.org/10.1161/Hypertensionaha.115.05469
Kim CM, Park HH (2020) Comparison of target recognition by TRAF1 and TRAF2. Int J Mol Sci 21:2895. https://doi.org/10.3390/ijms21082895
Kim CM, Choi JY, Bhat EA, Jeong JH, Son YJ, Kim S, Park HH (2016) Crystal structure of TRAF1 TRAF domain and its implications in the TRAF1-mediated intracellular signaling pathway. Sci Rep 6:25526. https://doi.org/10.1038/srep25526
Kim CM, Jeong JH, Son YJ, Choi JH, Kim S, Park HH (2017a) Molecular basis for TANK recognition by TRAF1 revealed by the crystal structure of TRAF1/TANK complex. FEBS Lett 591:810–821. https://doi.org/10.1002/1873-3468.12584
Kim CM, Son YJ, Kim S, Kim SY, Park HH (2017b) Molecular basis for unique specificity of human TRAF4 for platelets GPIbbeta and GPVI. Proc Natl Acad Sci USA 114:11422–11427. https://doi.org/10.1073/pnas.1708688114
Kurreeman FA, Goulielmos GN, Alizadeh BZ, Rueda B, Houwing-Duistermaat J, Sanchez E, Bevova M, Radstake TR, Vonk MC, Galanakis E, Ortego N, Verduyn W, Zervou MI, Roep BO, Dema B, Espino L, Urcelay E, Boumpas DT, van den Berg LH, Wijmenga C, Koeleman BP, Huizinga TW, Toes RE, Martin J, Group A, Consortium S (2010) The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Ann Rheum Dis 69:696–699. https://doi.org/10.1136/ard.2008.106567
Lalani AI, Zhu S, Gokhale S, Jin J, Xie P (2018) TRAF molecules in inflammation and inflammatory diseases. Curr Pharmacol Rep 4:64–90. https://doi.org/10.1007/s40495-017-0117-y
Lenin R, Sankaramoorthy A, Mohan V, Balasubramanyam M (2015) Altered immunometabolism at the interface of increased endoplasmic reticulum (ER) stress in patients with type 2 diabetes. J Leukoc Biol 98:615–622. https://doi.org/10.1189/jlb.3A1214-609R
Li C, Ni CZ, Havert ML, Cabezas E, He J, Kaiser D, Reed JC, Satterthwait AC, Cheng G, Ely KR (2002) Downstream regulator TANK binds to the CD40 recognition site on TRAF3. Structure 10:403–411. https://doi.org/10.1016/S0969-2126(02)00733-5
Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, Yang G, Sheng YQ, Xiao LB, Dong X, Ma WY, Bode AM, Cao Y, Dong ZG (2013) TRAF4 Is a critical molecule for akt activation in lung cancer. Can Res 73:6938–6950. https://doi.org/10.1158/0008-5472.Can-13-0913
Li J, Wang P, Xie Z, Wang S, Cen S, Li M, Liu W, Tang S, Ye G, Zheng G, Su H, Ma M, Wu X, Wu Y, Shen H (2019) TRAF4 positively regulates the osteogenic differentiation of mesenchymal stem cells by acting as an E3 ubiquitin ligase to degrade Smurf2. Cell Death Differ 26:2652–2666. https://doi.org/10.1038/s41418-019-0328-3
Liu G, Guo H, Guo C, Zhao S, Gong D, Zhao Y (2011) Involvement of IRE1alpha signaling in the hippocampus in patients with mesial temporal lobe epilepsy. Brain Res Bull 84:94–102. https://doi.org/10.1016/j.brainresbull.2010.10.004
Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914–918. https://doi.org/10.1038/nature06797
McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, Keegan D, Byrne K, Crowe E, Sexton G, Malone K, Harris RA, Kellermayer R, Mill J, Cullen G, Doherty GA, Mulcahy H, Murphy TM (2016) DNA methylation profiling in inflammatory bowel disease provides new insights into disease pathogenesis. J Crohns Colitis 10:77–86. https://doi.org/10.1093/ecco-jcc/jjv176
McGowan J, Peter C, Kim J, Popli S, Veerman B, Saul-McBeth J, Conti H, Pruett-Miller SM, Chattopadhyay S, Chakravarti R (2020) 14–3-3zeta-TRAF5 axis governs interleukin-17A signaling. Proc Natl Acad Sci USA 117:25008–25017. https://doi.org/10.1073/pnas.2008214117
Meng QB, Zheng MQ, Liu HB, Song CZ, Zhang WS, Yan J, Qin L, Liu XL (2012) TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem 371:177–186. https://doi.org/10.1007/s11010-012-1434-4
Middleton AJ, Budhidarmo R, Das A, Zhu JY, Foglizzo M, Mace PD, Day CL (2017) The activity of TRAF RING homo- and heterodimers is regulated by zinc finger 1. Nat Commun 8:1788. https://doi.org/10.1038/s41467-017-01665-3
Missiou A, Kostlin N, Varo N, Rudolf P, Aichele P, Ernst S, Munkel C, Walter C, Stachon P, Sommer B, Pfeifer D, Zirlik K, MacFarlane L, Wolf D, Tsitsikov E, Bode C, Libby P, Zirlik A (2010a) Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation 121:2033–2044. https://doi.org/10.1161/CIRCULATIONAHA.109.895037
Missiou A, Rudolf P, Stachon P, Wolf D, Varo N, Aichele P, Colberg C, Hoppe N, Ernst S, Munkel C, Walter C, Sommer B, Hilgendorf I, Nakano H, Bode C, Zirlik A (2010b) TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res 107:757–766. https://doi.org/10.1161/CIRCRESAHA.110.219295
Momeni M, Zainodini N, Bidaki R, Hassanshahi G, Daneshvar H, Khaleghinia M, Ebrahim M, Karimi-Googheri M, Askari A, Arababadi MK, Kennedy D (2014) Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients. Hum Immunol 75:15–19. https://doi.org/10.1016/j.humimm.2013.09.015
Moriya J, Takeuchi K, Tai K, Arai K, Kobayashi N, Yoneda N, Fukunishi Y, Inoue A, Kihara M, Murakami T, Chiba K, Shimada I (2015) Structure-based development of a protein-protein interaction inhibitor targeting tumor necrosis factor receptor-associated factor 6. J Med Chem 58:5674–5683. https://doi.org/10.1021/acs.jmedchem.5b00778
Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, Hermansson A, Dimitriou H, Bengoechea-Alonso MT, Ericsson J, Heldin CH, Landstrom M (2011) TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2:330. https://doi.org/10.1038/ncomms1332
Myles A, Rahman MT, Aggarwal A (2012) Membrane-bound toll-like receptors are overexpressed in peripheral blood and synovial fluid mononuclear cells of enthesitis-related arthritis category of juvenile idiopathic arthritis (JIA-ERA) patients and lead to secretion of inflammatory mediators. J Clin Immunol 32:488–496. https://doi.org/10.1007/s10875-011-9640-5
Nagel I, Bug S, Tonnies H, Ammerpohl O, Richter J, Vater I, Callet-Bauchu E, Calasanz MJ, Martinez-Climent JA, Bastard C, Salido M, Schroers E, Martin-Subero JI, Gesk S, Harder L, Majid A, Dyer MJ, Siebert R (2009) Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia 23:2153–2155. https://doi.org/10.1038/leu.2009.149
Namjou B, Choi CB, Harley IT, Alarcon-Riquelme ME, Network B, Kelly JA, Glenn SB, Ojwang JO, Adler A, Kim K, Gallant CJ, Boackle SA, Criswell LA, Kimberly RP, Brown EE, Edberg J, Alarcon GS, Stevens AM, Jacob CO, Gilkeson GS, Kamen DL, Tsao BP, Anaya JM, Kim EM, Park SY, Sung YK, Guthridge JM, Merrill JT, Petri M, Ramsey-Goldman R, Vila LM, Niewold TB, Martin J, Pons-Estel BA, Genoma en Lupus N, Vyse TJ, Freedman BI, Moser KL, Gaffney PM, Williams AH, Comeau ME, Reveille JD, Kang C, James JA, Scofield RH, Langefeld CD, Kaufman KM, Harley JB, Bae SC (2012) Evaluation of TRAF6 in a large multiancestral lupus cohort. Arthritis Rheum 64:1960–1969. https://doi.org/10.1002/art.34361
Ni CZ, Welsh K, Leo E, Chiou CK, Wu H, Reed JC, Ely KR (2000) Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci USA 97:10395–10399. https://doi.org/10.1073/pnas.97.19.10395
Niu F, Ru H, Ding W, Ouyang S, Liu ZJ (2013) Structural biology study of human TNF receptor associated factor 4 TRAF domain. Protein Cell 4:687–694. https://doi.org/10.1007/s13238-013-3068-z
Otto C, Giefing M, Massow A, Vater I, Gesk S, Schlesner M, Richter J, Klapper W, Hansmann ML, Siebert R, Kuppers R (2012) Genetic lesions of the TRAF3 and MAP3K14 genes in classical hodgkin lymphoma. Br J Haematol 157:702–708. https://doi.org/10.1111/j.1365-2141.2012.09113.x
Park HH (2018) Structure of TRAF family: current understanding of receptor recognition. Front Immunol 9:1999. https://doi.org/10.3389/fimmu.2018.01999
Park YC, Burkitt V, Villa AR, Tong L, Wu H (1999) Structural basis for self-association and receptor recognition of human TRAF2. Nature 398:533–538. https://doi.org/10.1038/19110
Park YC, Ye H, Hsia C, Segal D, Rich RL, Liou H-L, Myszka DG, Wu H (2000) A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell 101:777–787. https://doi.org/10.1016/S0092-8674(00)80889-2
Park J, Cho J, Song EJ (2020a) Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharmacal Res 43:1144–1161. https://doi.org/10.1007/s12272-020-01281-8
Park Y, Pang K, Park J, Hong E, Lee J, Ooshima A, Kim HS, Cho JH, Han Y, Lee C, Song YS, Park KS, Yang KM, Kim SJ (2020b) Destablilization of TRAF6 by DRAK1 suppresses tumor growth and metastasis in cervical cancer cells. Cancer Res 80:2537–2549. https://doi.org/10.1158/0008-5472.Can-19-3428
Perez de Diego R, Sancho-Shimizu V, Lorenzo L, Puel A, Plancoulaine S, Picard C, Herman M, Cardon A, Durandy A, Bustamante J, Vallabhapurapu S, Bravo J, Warnatz K, Chaix Y, Cascarrigny F, Lebon P, Rozenberg F, Karin M, Tardieu M, Al-Muhsen S, Jouanguy E, Zhang SY, Abel L, Casanova JL (2010) Human TRAF3 adaptor molecule deficiency leads to impaired toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33:400–411. https://doi.org/10.1016/j.immuni.2010.08.014
Potter C, Eyre S, Cope A, Worthington J, Barton A (2007) Investigation of association between the TRAF family genes and RA susceptibility. Ann Rheum Dis 66:1322–1326. https://doi.org/10.1136/ard.2006.065706
Qiao YQ, Shen J, Gu Y, Tong JL, Xu XT, Huang ML, Ran ZH (2013) Gene expression of tumor necrosis factor receptor associated-factor (TRAF)-1 and TRAF-2 in inflammatory bowel disease. J Dig Dis 14:244–250. https://doi.org/10.1111/1751-2980.12044
Raghav SK, Gupta B, Agrawal C, Chaturvedi VP, Das HR (2006) Expression of TNF-alpha and related signaling molecules in the peripheral blood mononuclear cells of rheumatoid arthritis patients. Mediat Inflamm 2006:12682. https://doi.org/10.1155/MI/2006/12682
Rajabi P, Alaee M, Mousavizadeh K, Samadikuchaksaraei A (2012) Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis. Inflamm Res 61:1347–1354. https://doi.org/10.1007/s00011-012-0535-6
Reuss R, Mirau A, Mistarz M, Kraus J, Bodeker RH, Oschmann P (2013) TRAF2 is upregulated in relapsing-remitting multiple sclerosis. NeuroImmunoModulation 20:177–183. https://doi.org/10.1159/000346794
Robeson AC, Lindblom KR, Wojton J, Kornbluth S, Matsuura K (2018) Dimer-specific immunoprecipitation of active caspase-2 identifies TRAF proteins as novel activators. EMBO J 37:e97072. https://doi.org/10.15252/embj.201797072
Rothe M, Wong SC, Henzel WJ, Goeddel DV (1994) A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681–692. https://doi.org/10.1016/0092-8674(94)90532-0
Rousseau A, McEwen AG, Poussin-Courmontagne P, Rognan D, Nomine Y, Rio MC, Tomasetto C, Alpy F (2013) TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration. PLoS Biol 11:e1001726. https://doi.org/10.1371/journal.pbio.1001726
Rousseau A, Wilhelm LP, Tomasetto C, Alpy F (2014) The phosphoinositide-binding protein TRAF4 modulates tight junction stability and migration of cancer cells. Tissue Barriers 2:e975597. https://doi.org/10.4161/21688370.2014.975597
Sajadi SMA, Mirzaei V, Hassanshahi G, Khorramdelazad H, Daredor HY, Hosseini SMH, Moogooi M, Ravary A, Arababadi MK, Kennedy D (2013) Decreased expressions of toll-like receptor 9 and its signaling molecules in chronic hepatitis B virus-infected patients. Arch Pathol Lab Med 137:1674–1679. https://doi.org/10.5858/arpa.2012-0415-OA
Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts S, Lameijer M, Gijbels MJ, Beckers L, den Toom M, Slutter B, Kuiper J, Duchene J, Aslani M, Megens RTA, van Tiel CM, Veer C, Kooij G, Schrijver R, Hoeksema MA, Boon L, Fay F, Tang J, Baxter S, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MPJ, Nicolaes GA, Mulder WJM, Weber C, Lutgens E (2018) Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. J Am Coll Cardiol 71:527–542. https://doi.org/10.1016/j.jacc.2017.11.05
Shen J, Qiao YQ, Ran ZH, Wang TR (2013a) Different activation of TRAF4 and TRAF6 in inflammatory bowel disease. Mediat Inflamm 2013:647936. https://doi.org/10.1155/2013/647936
Shen J, Qiao YQ, Ran ZH, Wang TR (2013b) Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease. Int J Med Sci 10:156–163. https://doi.org/10.7150/ijms.5457
Shi Z, Zhang Z, Zhang Z, Wang Y, Li C, Wang X, He F, Sun L, Jiao S, Shi W, Zhou Z (2015) Structural Insights into mitochondrial antiviral signaling protein (MAVS)-tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling. J Biol Chem 290:26811–26820. https://doi.org/10.1074/jbc.M115.666578
Slotwinski R, Sarnecka A, Dabrowska A, Kosalka K, Wachowska E, Balan BJ, Jankowska M, Korta T, Niewinski G, Kanski A, Mikaszewska-Sokolewicz M, Omidi M, Majewska K, Slotwinska SM (2015) Innate immunity gene expression changes in critically ill patients with sepsis and disease-related malnutrition. Cent Eur J Immunol 40:311–324. https://doi.org/10.5114/ceji.2015.54593
So T, Nagashima H, Ishii N (2015) TNF receptor-associated factor (TRAF) signaling network in CD4(+) T-lymphocytes. Tohoku J Exp Med 236:139–154. https://doi.org/10.1620/tjem.236.139
Song HY, Rothe M, Goeddel DV (1996) The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci USA 93:6721–6725. https://doi.org/10.1073/pnas.93.13.6721
Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M (1997) Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94:9792–9796
Song ZJ, Yao CL, Yin J, Tong CY, Zhu DM, Sun Z, Jiang JJ, Shao M, Zhang YP, Deng Z, Tao ZG, Sun S, Bai CX (2012) Genetic variation in the TNF receptor-associated factor 6 gene is associated with susceptibility to sepsis-induced acute lung injury. J Transl Med 10:166. https://doi.org/10.1186/1479-5876-10-166
Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-kappa B pathways in human lung cancer. J Clin Investig 121:4095–4105. https://doi.org/10.1172/Jci58818
Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, Vignali DA, Bergsagel PL, Karin M (2008) Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 9:1364–1370. https://doi.org/10.1038/ni.1678
Wang XW, Yang J, Han L, Zhao KX, Wu QS, Bao LM, Li ZY, Lv L, Li B (2015) TRAF5-mediated Lys-63-linked polyubiquitination plays an essential role in positive regulation of RORt in promoting IL-17A expression. J Biol Chem 290:29086–29094. https://doi.org/10.1074/jbc.M115.664573
Wang PX, Zhang XJ, Luo PC, Jiang X, Zhang P, Guo JH, Zhao GN, Zhu XY, Zhang Y, Yang SJ, Li HL (2016) Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nat Commun 7:10592. https://doi.org/10.1038/ncomms10592
Wang QS, Gao G, Zhang TS, Yao K, Chen HY, Park MH, Yamamoto H, Wang KK, Ma WY, Malakhova M, Bode AM, Dong ZG (2018) TRAF1 is critical for regulating the BRAF/MEK/ERK pathway in non-small cell lung carcinogenesis. Cancer Res 78:3982–3994. https://doi.org/10.1158/0008-5472.Can-18-0429
Wang XF, Gao S, Hao ZX, Tang T, Liu FS (2020) Involvement of TRAF6 in regulating immune defense and ovarian development in Musca domestica. Int J Biol Macromol 153:1262–1271. https://doi.org/10.1016/j.ijbiomac.2019.10.259
Wu D, Lee YCG, Liu HC, Yuan RY, Chiou HY, Hung CH, Hu CJ (2013) Identification of TLR downstream pathways in stroke patients. Clin Biochem 46:1058–1064. https://doi.org/10.1016/j.clinbiochem.2013.05.059
Xiang Q, Chen L, Fang J, Hou SP, Wei L, Bai L, Liu YJ, Zhou Y, Kijlstra A, Yang PZ (2013) TNF receptor-associated factor 5 gene confers genetic predisposition to acute anterior uveitis and pediatric uveitis. Arthritis Res Ther 15:R113. https://doi.org/10.1186/ar4293
Xiang Q, Chen L, Hou SP, Fang J, Zhou Y, Bai L, Liu YJ, Kijlstra A, Yang PZ (2014) TRAF5 and TRAF3IP2 gene polymorphisms are associated with behcet’s disease and vogt-koyanagi-harada syndrome: a case-control study. PLoS ONE 9:e84214. https://doi.org/10.1371/journal.pone.0084214
Xie P (2013) TRAF molecules in cell signaling and in human diseases. J Mol Signal 8:7. https://doi.org/10.1186/1750-2187-8-7
Yamamoto H, Ryu JY, Min E, Oi N, Bai RH, Zykova TA, Yu DH, Moriyama K, Bode AM, Dong Z (2017) TRAF1 is critical for DMBA/solar UVR-induced skin carcinogenesis. J Investig Dermatol 137:1322–1332. https://doi.org/10.1016/j.jid.2016.12.026
Yang XD, Sun SC (2015) Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol Rev 266:56–71. https://doi.org/10.1111/imr.12311
Ye H, Park YC, Kreishman M, Kieff E, Wu H (1999) The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 4:321–330. https://doi.org/10.1016/s1097-2765(00)80334-2
Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H (2002) Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443–447. https://doi.org/10.1038/nature00888
Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, Zheng L, Rich R, Campos AD, Myszka DG, Lenardo MJ, Darnay BG, Wu H (2009) E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 16:658–666. https://doi.org/10.1038/nsmb.1605
Yoon JH, Cho YJ, Park HH (2014) Structure of the TRAF4 TRAF domain with a coiled-coil domain and its implications for the TRAF4 signalling pathway. Acta Crystallogr D Biol Crystallogr 70:2–10. https://doi.org/10.1107/S139900471302333X
Zapata JM, Lefebvre S, Reed JC (2007) Targeting TRAfs for therapeutic intervention. Adv Exp Med Biol 597:188–201. https://doi.org/10.1007/978-0-387-70630-6_15
Zhang P, Reichardt A, Liang HH, Aliyari R, Cheng D, Wang YY, Xu F, Cheng GH, Liu YF (2012) Single amino acid substitutions confer the antiviral activity of the TRAF3 adaptor protein onto TRAF5. Sci Signal 5:ra81. https://doi.org/10.1126/scisignal.2003152
Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li Y, Bauer A, Rousseau A, Sheppard KA, Mickanin C, Kuppen PJ, Lu CX, Ten Dijke P (2013) TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell 51:559–572. https://doi.org/10.1016/j.molcel.2013.07.014
Zhang D, Liu X, Chen X, Gu J, Li F, Zhang W, Zheng Y (2014) Role of the MAPKs/TGF-beta1/TRAF6 signaling pathway in atrial fibrosis of patients with chronic atrial fibrillation and rheumatic mitral valve disease. Cardiology 129:216–223. https://doi.org/10.1159/000366096
Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, Urowitz MB, Fortin PR, Wither JE (2010) Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosus. J Rheumatol 37:1658–1666. https://doi.org/10.3899/jrheum.091123
Zhu LJ, Yang TC, Wu Q, Yuan LP, Chen ZW, Luo MH, Zeng HO, He DL, Mo CJ (2017a) Tumor necrosis factor receptor-associated factor (TRAF) 6 inhibition mitigates the pro-inflammatory roles and proliferation of rheumatoid arthritis fibroblast-like synoviocytes. Cytokine 93:26–33. https://doi.org/10.1016/j.cyto.2017.05.001
Zhu Y, Xue Z, Di L (2017b) Regulation of MiR-146a and TRAF6 in the diagnose of lupus nephritis. Med Sci Monit 23:2550–2557. https://doi.org/10.12659/msm.900667
Zhu S, Jin J, Gokhale S, Lu AM, Shan H, Feng J, Xie P (2018) Genetic alterations of TRAF proteins in human cancers. Front Immunol 9:2111. https://doi.org/10.3389/fimmu.2018.02111
Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, Ernst S, Aikawa M, Nakano H, Tsitsikov E, Schonbeck U (2007) TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol 27:1101–1107. https://doi.org/10.1161/ATVBAHA.107.140566
Zucchelli S, Marcuzzi F, Codrich M, Agostoni E, Vilotti S, Biagioli M, Pinto M, Carnemolla A, Santoro GS, Persichetti F (2011) Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein and promotes its atypical ubiquitination to enhance aggregate formation. J Biol Chem 286:25108–25117. https://doi.org/10.1074/jbc.M110.187591
Acknowledgements
This study was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF) of the Ministry of Education, Science, and Technology (NRF-2017M3A9D8062960, and NRF-2021R1A2C3003331).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that they have no conflict of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Park, H.H. Structural feature of TRAFs, their related human diseases and therapeutic intervention. Arch. Pharm. Res. 44, 475–486 (2021). https://doi.org/10.1007/s12272-021-01330-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01330-w